Skip to content
The Policy VaultThe Policy Vault

sodium phenylbutyrate (generic)CareFirst (Caremark)

Urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)

Initial criteria

  • Diagnosis is confirmed by enzymatic, biochemical, or genetic testing
  • Member has elevated plasma ammonia levels at baseline
  • If the request is for Olpruva, patient weighs 20 kg or greater
  • If the request is for Olpruva, patient has a body surface area (BSA) of 1.2 m2 or greater

Reauthorization criteria

  • Member is experiencing benefit from therapy as evidenced by a reduction in plasma ammonia levels from baseline

Approval duration

12 months